Abstract
Development of antibiotics to treat infections caused by multidrug-resistant gram-negative bacilli has lagged significantly behind development of antibiotics to treat infections with gram-positive pathogens. Although a few promising drugs have entered early clinical development, more must be done to preserve the utility of currently available antibiotics and to ensure a pipeline of efficacious, safe antibacterials.
Publisher
Cambridge University Press (CUP)
Subject
Infectious Diseases,Microbiology (medical),Epidemiology
Reference11 articles.
1. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
2. Cubist Pharmaceuticals. Our advancing pipeline, http://www.cubist.com/products/index.php#pipeline. Accessed March 19, 2010.
3. In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States
4. Novexel. Mature and diverse pipeline, http://www.novexel.com/contenu.php?page = pipeline. Accessed April 18, 2010.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献